Abstract
Background
Nonalcoholic fatty liver disease (NAFLD) is a common chronic disease that is rapidly increasing worldwide.
Aim
The aim of this study was to investigate the risk factors associated with NAFLD in nondiabetics from South India.
Participants and methods
We recruited 345 asymptomatic participants consecutively, and the study period was between January 2014 and December 2017. All participants underwent risk factor evaluation, fasting serum lipid profile, C-reactive protein (CRP), hemoglobin A1c, liver function test, and abdominal ultrasound.
Results
Of 345 participants, men represented 213 (71%). The mean age of the participants was 58.4±11.1 years, with age range from 24–68 years. Prevalence of NAFLD was seen in 22%. On risk factor evaluation, 107 (31%) were hypertensive, 89 (25.7%) smoked, 52 (15%) were overweight, 110 (24.9%) were obese, and 113 (32.7%) had dyslipidemia. The mean CRP was 12.7±9.5 mg/l. High γ-glutamyl transferase levels, elevated CRP levels, obesity (45, 59.2%), high total cholesterol (49, 64.4%), low levels of high-density lipoprotein (28, 36.8%), high levels of low-density lipoprotein (27, 35.5%), and high triglycerides (31, 40.7%) were significantly associated with NALFD compared with non-NAFLD. After adjustment using multiple regression analysis, obesity (odds ratio: 3.5; 95% CI: 2.18–6.16), high total cholesterol [odds ratio: 4.9; 95% confidence interval (CI): 2.91–9.43], low high-density lipoprotein (odds ratio: 2.3; 95% CI: 1.20–4.47), high low-density lipoprotein (odds ratio: 2.9; 95% CI: 1.58–6.17), high triglycerides (odds ratio: 2.4; 95% CI: 1.33–4.60), and elevated CRP levels (odds ratio: 2.0; 95% CI: 1.21–3.39) were significantly associated with NAFLD.
Conclusion
Our study established obesity, CRP positivity, and dyslipidemia as independently associated with NAFLD in South Indian patients.
Article PDF
Similar content being viewed by others
References
Kalra S, Vithalani M, Gulati G, Kulkarni CM, Kadam Y, Pallivathukkal J, et al. Study of prevalence of nonalcoholic fatty liver disease (NAFLD) in type 2 diabetes patients in India (SPRINT). J Assoc Physicians India 2013; 61:448–453.
Suzuki A, Angulo P, Lymp J, St Sauver J, Muto A, Okada T, et al. Chronological development of elevated aminotransferases in a nonalcoholic population. Hepatology 2005; 41:64–71.
Amarapurkar DN, Hashimoto E, Lesmana LA, Sollano JD, Chen PJ, Goh KL. How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences? J Gastroenterol Hepatol 2007; 22:788–793.
Bellentani S, Scaglioni F, Marino M, Bedogni G. Epidemiology of nonalcoholic fatty liver disease. Dig Dis 2010; 28:155–161.
Duseja A. Nonalcoholic fatty liver disease in India – a lot done, yet more required. Indian J Gastroenterol 2010; 29:217–225.
Uchil D, Pipalia D, Chawla M, Patel R, Maniar S, Narayani, et al. Nonalcoholic fatty liver disease (NAFLD) – the hepatic component of metabolic syndrome. J Assoc Physicians India 2009; 57:201–204.
Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994; 107:1103–1109.
Mahaling DU, Basavaraj MM, Bika AJ. Comparison of lipid profile in different grades of non-alcoholic fatty liver disease diagnosed on ultrasound. Asian Pac J Trop Biomed 2013; 3:907–912.
Chaudhuri JR, Mridula KR, Anamika A, Boddu DB, Misra PK, Lingaiah A, et al. Deficiency of 25-hydroxyvitamin D and dyslipidemia in Indian subjects. J Lipids 2013; 2013:623420.
Chaudhuri JR, Mridula KR, Keerthi AS, Prakasham PS, Balaraju B, Bandaru VC. Association between Chlamydia pneumoniae and migraine: a study from a tertiary center in India. J Oral Facial Pain Headache 2016; 30:150–155.
Omagari K, Kadokawa Y, Masuda J, Egawa I, Sawa T, Hazama H, et al. Fatty liver in non-alcoholic non-overweight Japanese adults: incidence and clinical characteristics. J Gastroenterol Hepatol 2002; 17:1098–1105.
Lin YC, Lo HM, Chen JD. Sonographic fatty liver, overweight and ischemic heart disease. World J Gastroenterol 2005; 11:4838–4842.
Lizardi-Cervera J, Laparra DI, Chavez-Tapia NC, Ostos ME, Esquivel MU. Prevalence of NAFLD and metabolic syndrome in asymtomatics subjects. Rev Gastroenterol Mex 2006; 71:453–459.
Zelber-Sagi S, Nitzan-Kaluski D, Halpern Z, Oren R. Prevalence of primary non-alcoholic fatty liver disease in a population-based study and its association with biochemical and anthropometric measures. Liver Int 2006; 26:856–863.
Radu C, Grigorescu M, Crisan D, Lupsor M, Constantin D, Dina L. Prevalence and associated risk factors of non-alcoholic fatty liver disease in hospitalized patients. J Gastrointestin Liver Dis 2008; 17:255–260.
Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos Nutrition and Liver Study. Hepatology 2005; 42:44–52.
Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40:1387–1395.
Caldwell SH, Ikura Y, Iezzoni JC, Liu Z. Has natural selection in human populations produced two types of metabolic syndrome (with and without fatty liver)? J Gastroenterol Hepatol 2007; 22(Suppl 1):S11–S19.
Amarapurkar DN, Amarapurkar AD. Nonalocholic steatohepatitis: clinicopathologic profile. J Assoc Physicians India 2000; 48:311–313.
Kim IH, Kisseleva T, Brenner DA. Aging and liver disease. Curr Opin Gastroenterol 2015; 31:184–191.
Cotrim HP, Parise ER, Oliveira CP, Leite N, Martinelli A, Galizzi J, et al. Nonalcoholic fatty liver disease in Brazil: clinical and histological profile. Ann Hepatol 2011; 10:33–37.
Donati G, Stagni B, Piscaglia F, Venturoli N, Morselli-Labate AM, Rasciti L, et al. Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance. Gut 2004; 53:1020–1023.
Fallo F, Dalla PA, Sonino N, Lupia M, Tona F, Federspil G, et al. Nonalcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in essential hypertension. Nutr Metab Cardiovasc Dis 2009; 19:646–653.
Zein CO, Unalp A, Colvin R, Liu YC, McCullough AJ, Nonalcoholic Steatohepatitis Clinical Research Network. Smoking and severity of hepatic fibrosis in nonalcoholic fatty liver disease. J Hepatol 2011; 54:753–759.
Rivera CA. Risk factors and mechanisms of non-alcoholic steatohepatitis. Pathophysiology 2008; 15:109–114.
De Sousa TF, Nahas MV, Silva DA, del Duca GF, Peres MA. Factors associated with central obesity in adults from Florianópolis, Santa Catarina: a population based-study. Rev Bras Epidemiol 2011; 14:296–309.
Kim HJ, Kim HJ, Lee KE, Kim DJ, Kim SK, Ahn CW, et al. Metabolic significance of nonalcoholic fatty liver disease in nonobese, nondiabetic adults. Arch Intern Med 2004; 164:2169–2175.
Bellentani S, Saccoccio G, Masutti F, Crocè LS, Brandi G, Sasso F, et al. Prevalence of and risk factors for hepatic steatosis in NorthernItaly. Ann Intern Med 2000; 132:112–117.
Loria P, Carulli L, Bertolotti M, Lonardo A. Endocrine and liver interaction: the role of endocrine pathways in NASH. Nat Rev Gastroenterol Hepatol 2009; 6:236–247.
Prashanth M, Ganesh HK, Vima MV, John M, Bandgar T, Joshi SR, et al. Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. J Assoc Physicians India 2009; 57:205–210.
Jali MV, Kambar S, Jali SM, Hiremath MB. Prevalence of non-alcoholic fatty liver disease among type-2 diabetes mellitus patients – a cross-sectional hospital based study. Al Ameen J Med Sci 2015; 8:50–54.
Agrawal R, Mishra S, Dixit VK, Rai S. Association of non-alcoholic fatty liver disorder with obesity. Indian J Prev Soc Med 2009; 40:126–129.
Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37:917–923.
Duseja A, Das R, Nanda M, Das A, Garewal G, Chawla Y. Non alcoholic steatohepatitis in Asian Indians in neither associated with iron overload with HFE genemutations. World J Gastroenterol 2005; 11:393–395.
Nigam P, Bhatt SP, Misra A, Vaidya M, Dasgupta J, Chadha DS. Nonalcoholic fatty liver disease is closely associated with sub-clinical inflammation: a case-control study on Asian Indians in North India. PLoS ONE 2013; 8:e49286.
Amirkalali B, Poustchi H, Keyvani H, Khansari MR, Ajdarkosh H, Maadi M, et al. Prevalence of non-alcoholic fatty liver disease and its predictors in north of Iran. Iran J Public Health 2014; 43:1275–1283.
Haukeland JW, Damås JK, Konopski Z, Loberg EM, Haaland T, Goverud I, et al. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J Hepatol 2006; 44:1167–1174.
Oruc N, Ozutemiz O, Yuce G, Akarca US, Ersoz G, Gunsar F, et al. Serum procalcitonin and CRP levels in non-alcoholic fatty liver disease: a case-control study. BMC Gastroenterol 2009; 9:16.
Chandalia M, Cabo-Chan AV Jr, Devaraj S, Jialal I, Grundy SM, et al. Elevated plasma high-sensitivity C-reactive protein concentrations in Asian Indians living in the United States. J Clin Endocrinol Metab 2003; 88:3773–3776.
Park SH, Kim BI, Yun JW, Kim JW, Park DI, Cho YK, et al. Insulin resistance and C-reactive protein as independent risk factors for non-alcoholic fatty liver disease in non-obese Asian men. J Gastroenterol Hepatol 2005; 19:694–698.
Assy N, Schlesinger S, Hussein O. Elevated plasma protein C correlates with the presence of fatty liver. Gut 2005; 54:729.
Syn WK, Nightingale P, Bateman JM. Non-alcoholic fatty liver disease in a district general hospital: clinical presentation and risk factors. Hepatol Int 2008; 2:190–195.
Taseer IH, Hussain L, Safdar S, Mirbahar AM, Ahmad I. Frequency of non-alcoholic fatty liver disease (NAFLD) and its biochemical derangements in type 2 diabetic patients. Pak J Med Sci 2009; 25:817–820.
Saxena T, Arya A, Rathore AJ, Rajak N, Naz S, Shah R. GGT and SGPT – a rising marker in diagnosis of non-alcoholic fatty liver disease. Biomed Pharmacol J 2014; 7:277–280.
Wang J, Li P, Jiang Z, Yang Q, Mi Y, Liu Y, et al. Diagnostic value of alcoholic liver disease (ALD)/nonalcoholic fatty liver disease (NAFLD) index combined with γ-glutamyl transferase in differentiating ALD and NAFLD. Korean J Intern Med 2016; 31:479–487.
Joy D, Thava VR, Scot BB. Diagnosis of fatty liver disease: is biopsy necessary?. Eur J Gastroenterol Hepatol 2003; 15:539–543.
Author information
Authors and Affiliations
Corresponding author
Additional information
This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
Rights and permissions
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Bandaru, V.C.S.S., Chaudhury, J.R., Lalitha, P. et al. Prevalence of asymptomatic nonalcoholic fatty liver disease in nondiabetic participants: a study from south india. Egypt J Intern Med 31, 92–98 (2019). https://doi.org/10.4103/ejim.ejim_76_18
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.4103/ejim.ejim_76_18